Abstract: TH-PO969
Depressive Symptoms and RANKL/OPG in Hemodialysis
Session Information
- Physical Activity and Lifestyle in Kidney Diseases
October 24, 2024 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Health Maintenance, Nutrition, and Metabolism
- 1500 Health Maintenance, Nutrition, and Metabolism
Authors
- Kim, Heejeong, Department of Internal Medicine, Veterans Healthcare Service (VHS) Medical Center, Seoul, Korea (the Republic of)
- Lee, Dong-Young, Department of Internal Medicine, Veterans Healthcare Service (VHS) Medical Center, Seoul, Korea (the Republic of)
Background
Depression and osteoporosis are prevalent in dialysis patients. Denosumab and romosozumab similarly block RANKL. While RANKL causes bone resorption after binding RANKL, binding with OPG inhibits bone resorption. A recent mice study, denosumab improved depressive-like phenotype by inhibiting RANKL. OPG was linked to depression. This study aimed to explore the association of depressive symptoms with RANKL/OPG in HD patients.
Methods
We conducted a cross-sectional study involving 172 HD patients, measuring plasma RANKL, OPG levels. Logistic regression analysis was performed to evaluate the effect of RANKL and OPG on the depressive symptoms.
Results
The depressive symptoms were observed in 90(52.3%) subjects. RANKL tertile 3 had negative association with BDI score(β-4.527, 95% CI -8.310~-0.743) in univariate analysis. This association persisted after multivariate adjustments(β-5.603, 95% CI -9.715~-1.491) in linear regression. In logistic regression between RANKL tertiles and depressive symptoms, RANKL tertile 3 had significantly lower unadjusted OR (0.40, 95% CI 0.19~0.86), and multivariate-adjusted OR (0.31, 95% CI 0.12~0.82) for depressive symptoms.
Conclusion
OPG wasn't significantly associated with depressive symptoms. Higher plasma RANKL levels were associated with lower depressive symptoms in HD patients.
Odds ratios of plasma RANKL, OPG, and RANKL/OPG ratio for depressive symptoms
| OR (95% CI) Unadjusted | P value | OR (95% CI) Adjusted | P Value | |
| RANKL tertile 1 | Reference | Reference | ||
| RANKL tertile 2 | 0.51 (0.24-1.09) | 0.080 | 0.42 (0.16-1.09) | 0.074 |
| RANKL tertile 3 | 0.40 (0.19-0.86) | 0.018 | 0.31 (0.12-0.82) | 0.018 |
| OPG tertile 1 | Reference | Reference | ||
| OPG tertile 2 | 1.64 (0.78-3.44) | 0.191 | 0.59 (0.20-1.69) | 0.326 |
| OPG tertile 3 | 1.37 (0.66-2.85) | 0.401 | 0.29 (0.08-1.02) | 0.165 |
| RANKL/OPG tertile 1 | Reference | Reference | ||
| RANKL/OPG tertile 2 | 0.48 (0.23-1.03) | 0.059 | 0.51 (0.20-1.32) | 0.041 |
| RANKL/OPG tertile 3 | 0.35 (0.17-0.75) | 0.007 | 0.55 (0.21-1.42) | 0.256 |
RANKL receptor activator of nuclear factor-κB ligand, OPG Osteoprotegerin, OR Odds Ratio, CI Confidential Interval Multivariate, adjusted for age, sex, BMI, Diabetes mellitus, cardiovascular diseases, HD vintage, spKt/V, hsCRP